On December 16, 2025, MAIA Biotechnology, Inc. announced a securities purchase agreement to raise approximately $2.25 million by issuing 1,053,751 shares and warrants to accredited investors at $1.224 per share. The funds will be used for Phase II trial costs and working capital, with the closing expected on December 18, 2025.